Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neuphoria Therapeutics ( (NEUP) ) has shared an update.
On December 12, 2025, Neuphoria Therapeutics held its Annual Meeting of Shareholders, during which voting took place on four key proposals related to corporate governance and strategy. The proposals included the election of two Class I directors for a three-year term, the ratification of Wolf & Company P.C. as the company’s auditors for the fiscal year ending June 30, 2026, a non-binding vote on executive compensation, and a decision on the frequency of future advisory votes on executive pay. The results demonstrated shareholder support across all proposals, suggesting an alignment between company management and its shareholders on governance and strategic priorities.
The most recent analyst rating on (NEUP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Neuphoria Therapeutics stock, see the NEUP Stock Forecast page.
More about Neuphoria Therapeutics
Average Trading Volume: 1,580,291
Technical Sentiment Signal: Sell
Current Market Cap: $20.97M
Find detailed analytics on NEUP stock on TipRanks’ Stock Analysis page.